Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 3/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.32 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.32 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604445 | 0.90 | PRKCI (0.45) | PRKCIPRKCZHRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9104338 | 0.88 | HRH3 (0.43) | PRKCZHRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9232685 | 0.84 | HRH4 (0.39) | PRKCZHRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9099585 | 0.84 | HRH4 (0.53) | HRH4 | |
| Trifluoroacetic Acid SCHEMBL9100812 | 0.84 | HRH4 (0.42) | HRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9102466 | 0.84 | HRH4 (0.52) | HRH4 | |
| Trifluoroacetic Acid SCHEMBL9103184 | 0.83 | ADRB1 (0.38) | PRKCIPRKCZHRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9100766 | 0.83 | ADRB1 (0.35) | HRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9104180 | 0.82 | ADRB1 (0.35) | HRH4ADRB1 | |
| Trifluoroacetic Acid SCHEMBL9101425 | 0.81 | PRKCZ (0.44) | PRKCIPRKCZHRH4ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937075-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-8927555-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2015-01-06 | — | — | US | disclosed |
| US-8445482-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-21 | — | — | US | disclosed |
| US-8440654-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-14 | — | — | US | disclosed |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós i | 2012-09-20 | — | — | US | disclosed |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | Timoneda, Jesús Joanós | 2012-08-16 | — | — | US | disclosed |
| US-8193178-B2 | Thieno- and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208793-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | PRKCI 4579/4885PRKCZ 4205/4885HRH4 1/4885 |
| US-20120238544-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | PRKCI 4579/4885PRKCZ 4205/4885HRH4 1/4885 |
| US-20120214792-A1 | THIENO- ADN FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | PRKCI 4616/4885PRKCZ 4152/4885HRH4 1/4885 |
| US-20120270855-A1 | THIENO- AND FURO-PYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH3, HRH2 | PRKCI 4579/4885PRKCZ 4205/4885HRH4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.